Citations

Showing 10 of 108119 citations.

Poly (ADP-Ribose) Polymerase Inhibition for Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Placebo-Controlled Trials
Balko, Ryan , Hurley, Rachel M. , Jatoi, Aminah , Hurley, Rachel

Mayo Clinic

Journal of Palliative Medicine | March 6, 2019 | Volume: 22 | Issue: 8 | Pages: 977-980

10.1089/jpm.2018.0572 | PMID 30839241 Get It

Abstract Background: Chemotherapy-induced peripheral neuropathy is characterized by pain, numbness, and tingling in the hands and feet and by diminished quality of life. Multiple previous studies, mostly preclinical, suggest that poly (ADP-ribose) polymerase (PARP) inhibitors may help with these symptoms. Objective: To assess the relationship between PARP inhibition and prevention/palliation of peripheral neuropathy in a clinical setting. Design: Meta-analysis of placebo-controlled clinical trials with PARP inhibitors. Setting/Subjects: We conducted 9 literature searches that included PubMed and other sources to compile fully published placebo-controlled clinical trials that tested PARP inhibitors and that reported on peripheral neuropathy. Measurements: The relative risks for neuropathy of all grades based on PARP inhibition were calculated for each trial. Each trial was weighted by its respective sample size. A forest plot was constructed. Results: Five trials, inclusive of 843 patients, met this study's eligibility criteria. Four included a concomitant PARP inhibitor (either olaparib or veliparib) and paclitaxel, a neuropathy-causing chemotherapy agent; the remaining trial evaluated long-term monotherapy with olaparib. The pooled overall relative risk for the development of neuropathy with PARP inhibition was 1.06 (95% confidence interval: 1–1.4). Conclusions: PARP inhibition does not appear to reduce the risk of chemotherapy-induced peripheral neuropathy. Whether PARP inhibitors may palliate (rather than prevent) neuropathy remains an area in need of further investigation.
Hydrogen‐Peroxide‐Generating Electrochemical Scaffold Eradicates Methicillin‐Resistant Staphylococcus aureus Biofilms
Raval, Yash S. , Mohamed, Abdelrhman , Zmuda, Hannah , Patel, Robin , Zmuda, Hannah M, Patel, Robin , Zmuda, H M , Mohamed, A , Beyenal, Haluk , Raval, Yash S.

Mayo Clinic

Global Challenges | March 6, 2019 | Volume: 3 | Issue: 6 | Pages: No page available

10.1002/gch2.201800101 | PMID 31218078 Get It

AbstractIncreasing rates of chronic wound infections caused by antibiotic‐resistant bacteria are a crisis in healthcare settings. Biofilms formed by bacterial communities in these wounds create a complex environment, enabling bacteria to persist, even with antibiotic treatment. Wound infections caused by methicillin‐resistant Staphylococcus aureus (MRSA) are major causes of morbidity in clinical practice. There is a need for new therapeutic interventions not based on antibiotics. Hydrogen peroxide (H2O2) is a known antibacterial/antibiofilm agent, continuous delivery of which has been challenging. A conductive electrochemical scaffold (e‐scaffold) is developed, which is composed of carbon fabric that electrochemically reduces dissolved oxygen into H2O2 when polarized at −0.6 VAg/AgCl, as a novel antibiofilm wound dressing material. In this study, the in vitro antibiofilm activity of the e‐scaffold against MRSA is investigated. The developed e‐scaffold efficiently eradicates MRSA biofilms, based on bacterial quantitation and ATP measurements. Moreover, imaging hinted at the possibility of cell‐membrane damage as a mechanism of action. These results suggest that an H2O2‐generating e‐scaffold may be a novel platform for eliminating MRSA biofilms without using antibiotics and may be useful to treat chronic MRSA wound infections.
Image cytometry as an alternative to flow cytometry for the transplant histocompatibility crossmatch assay
Ramón, Daniel S. , Franks, Thomas, Jaramillo, Andrés , Paradis, Benjamin, Chan, Leo Li‐Ying , Jaramillo, Andres

Mayo Clinic

HLA | March 6, 2019 | Volume: 93 | Issue: 6 | Pages: 436-444

10.1111/tan.13515 | PMID 30838802 Get It

The lymphocyte crossmatch is currently the only cell‐based compatibility assay performed by histocompatibility laboratories for transplant purposes. While in many transplant programs the complement‐dependent cytotoxicity crossmatch (CDCXM) remains in use, when available, the flow cytometry crossmatch (FCXM) is the method of choice because of its superior sensitivity and specificity. Unfortunately, the maintenance and cost of a flow cytometer is a considerable limitation for small histocompatibility laboratories. Therefore, in this study, we evaluated the use of the Cellometer Vision CBA image cytometer (Nexcelom Bioscience LLC, Lawrence, Massachusetts) as an alternative instrument to perform the crossmatch assay. The 3‐color FCXM protocol was modified into two separate 2‐color panel image cytometry crossmatches (IXMs), one for T cells and one for B cells. After initial serum and cell incubation, a cocktail consisting of PE/Cy5‐conjugated anti‐human CD3 or CD19 and PE‐conjugated anti‐human IgG F(ab′)2was added to the T cell and B cell panels, respectively. The final cell preparation was added to a separate counting chamber. Images were captured using the Cellometer Vision CBA, an image cytometer designed for cell counting, size analysis and fluorescence intensity measurement. Thirty‐nine IXMs were performed and compared with the FCXM. We obtained a concordance sensitivity of 94.1% and 100% and specificity of 100% and 88.9% for T cells and B cells, respectively. The linearity of the system was verified using dilutions of a sample containing known donor‐specific anti‐HLA antibodies (DSA) against the target cells. This feasibility study demonstrates that the FCXM test could be easily adapted to the Cellometer Vision CBA image cytometer without compromising specificity and sensitivity. The low instrumentation cost, minimal maintenance, and simple operation allow for efficient implementation or transition from the FCXM to the IXM method.
Triple bridge of mechanical circulatory support to heart transplantation listing: A case report
Ahmed, Magdy M. El‐Sayed , Thomas, Mathew , Jacob, Samuel , Makey, Ian A. , Landolfo, Kevin , Belli, Erol, El-Sayed Ahmed, Magdy M , Landolfo, Kevin P, Pham, Si M. , Belli, Erol V, Thomas, Mathew

Mayo Clinic

SAGE Open Medical Case Reports | March 6, 2019 | Volume: 7 | Issue: No issue available | Pages: No page available

10.1177/2050313x19834816 | PMID 30858974 Get It

A 60-year-old male patient presented to an outside hospital with severe cardiogenic shock. A triple bridge of mechanical circulatory support was utilized to transition him to heart transplantation listing. Initially, coronary artery disease was percutaneously treated and Impella 2.5 was used as mechanical circulatory support for 5 days followed by the second Impella 2.5 for 4 days. Veno-arterial extracorporeal membrane oxygenation support was deployed for 16 days. This was exchanged for HeartWare ventricular assist device support as the third stage of mechanical circulatory support to heart transplantation listing. The patient experienced acute renal failure which was managed by continuous renal replacement therapy then intermittent hemodialysis with eventual complete recovery of the renal function. He was discharged home 56 days after HeartWare ventricular assist device implantation with stable hemodynamic, intact neurologic status and fully recovered renal function. Currently, the patient is listed for heart transplantation.
Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis
Sidana, Surbhi , Tandon, Nidhi , Ramı́rez-Alvarado, Marina , Murray, David , Kourelis, Taxiarchis , Kapoor, Prashant , Gonsalves, Wilson I. , Warsame, Rahma , Lacy, Martha Q. , Kyle, Robert A. , Kumar, Shaji , Ramirez-Alvarado, Marina, Murray, David L., Kourelis, Taxiarchis V, Buadi, Francis K. , Gonsalves, Wilson , Kumar, Shaji K , Sidana, Surbhi , Ramirez-Alvarado, Marina , Gertz, Morie A. , Dispenzieri, Angela , Rajkumar, S. Vincent , Leung, Nelson

Mayo Clinic

British Journal of Haematology | March 6, 2019 | Volume: 185 | Issue: 4 | Pages: 701-707

10.1111/bjh.15832 | PMID 30836444 Get It

SummaryThis study evaluated the differences in clinical features of 1077 newly diagnosed AL amyloidosis patients with renal involvement (n = 229, 21%), both cardiac and renal involvement (n = 443, 41%) and cardiac involvement (n = 405, 38%). Significant differences in dFLC (difference in involved and uninvolved light chains) were noted (renal, both, cardiac median: 83, 234 and 349 mg/l, P < 0.001). The proportion of patients with ≥ 10% bone marrow plasma cells (BMPCs) was lowest in renal only patients: 44%, 57%, 64%, respectively, P < 0.001. In a multivariate linear regression model incorporating organ involvement type and BMPCs ≥10%, organ involvement was a significant predictor of dFLC (P < 0.001). Median overall survival (OS) across the three groups was 83 vs. 19 vs. 16 months (P < 0.001) in patients not undergoing transplant and 5‐year OS in patients undergoing transplant was 90% vs. 75% vs. 64% (P = 0.007), respectively. In conclusion, renal involvement alone or renal + cardiac involvement in AL amyloidosis is associated with lower circulating light chain burden, which cannot be fully explained by BMPC burden alone. Increased sensitivity of the kidney to light chains, given significant interactions with the renal tubular system and secretion of modified light chain products may play a role in pathogenesis of renal AL amyloidosis and warrants further investigation.
Patent foramen ovale closure for secondary stroke prevention
Sievert, Horst, Holmes, David R. , Alkhouli, Mohamad

Mayo Clinic

European Heart Journal | March 5, 2019 | Volume: 40 | Issue: 28 | Pages: 2339-2350

10.1093/eurheartj/ehz157 | PMID 30957864 Get It

Abstract Transcatheter closure of patent foramen ovale (PFO) in patients with cryptogenic stroke is gaining momentum after the recent publication of four randomized clinical trials suggesting its benefit. This article provides a contemporary overview of the anatomy and pathophysiology of PFO, the available diagnostic tools for the assessment and risk stratification of PFO, and the current and future landscape of PFO closure devices and their optimal utilization. It also summarizes the current data on PFO closure for stroke prevention, and discusses the remaining open issues in the field of PFO closure.
Therapeutic Approaches to Aging—Reply
Kirkland, James L. , Tchkonia, Tamara, Tchkonia, Tamar

Mayo Clinic

JAMA | March 5, 2019 | Volume: 321 | Issue: 9 | Pages: 901

10.1001/jama.2018.20554 | PMID 30835305 Get It

Quantitative phenotype analysis to identify, validate and compare rat disease models
Zhao, Yiqing , Smith, Jennifer R. , Wang, Shur‐Jen , Dwinell, Melinda R. , Shimoyama, Mary

Mayo Clinic

Database | March 5, 2019 | Volume: 2019 | Issue: No issue available | Pages: No page available

10.1093/database/baz037 | PMID 30938777 Get It

The evolution of treatment and complications of esophageal food impaction
Schupack, Daniel , Lenz, Charles J., Geno, Debra M., Tholen, Crystal, Leggett, Cadman L. , Katzka, David A. , Alexander, Jeffrey A. , Schupack, Daniel A, Tholen, Crystal J, Leggett, Cadman L

Mayo Clinic

United European Gastroenterology Journal | March 5, 2019 | Volume: 7 | Issue: 4 | Pages: 548-556

10.1177/2050640619836052 | PMID 31065372 Get It

Background Esophageal food impaction is relatively common and increasing over time. Treatment ranges from medications to invasive endoscopic therapies. The endoscopic push technique has been advised against in favor of endoscopic retrieval for safety concerns. We sought to assess use patterns and safety of treatments for food impaction in a population‐based retrospective review. Methods A database of recorded esophageal food impactions in Olmsted County, MN, USA, from 1975–2011 was reviewed for patient demographics, treatment, and complications. Results A total of 645 impactions occurred, with increasing incidence over time, peaking at 23.2 per year (2000–2004). Medications (almost exclusively glucagon) were successful in relieving impactions 34.5% of the time when trialed. Urgent endoscopy was common (74.0%), as was the need for endoscopic therapy (67.1%). Endoscopic therapy increased over time, with the endoscopic push technique becoming most common. Esophageal complications (deep mucosal injury or perforation) increased over time but remained rare (peak 11%). There was no difference in complications between push and retrieval techniques. Conclusions The endoscopic push technique is safe in comparison to endoscopic retrieval in esophageal food impactions. While complications surrounding impaction have increased, they remain rare. Medication trials are reasonable, as long as they do not delay endoscopy, and may prevent the need for emergent endoscopy in one‐third of cases.
Primary Cutaneous Acral CD8+ T-Cell Lymphoma—A Single Center Review of 3 Cases and Recent Literature Review
Tjahjono, Leonardo , Davis, Mark D.P. , Comfere, Nneka I. , Tjahjono, Leonardo A, Tjahjono, L A , Witzig, Thomas E.

Mayo Clinic

The American Journal of Dermatopathology | March 5, 2019 | Volume: 41 | Issue: 9 | Pages: 644-648

10.1097/dad.0000000000001366 | PMID 31433793 Get It

Abstract: The recently published 2016 revision of the WHO classification of lymphoid neoplasms includes primary cutaneous acral CD8-positive T-cell lymphoma (PCATCL) as a provisional entity. This is a rare indolent lymphoma characterized by papules or nodules on the ear and a dermal infiltrate of CD8-positive T-lymphocytes with cytotoxic marker expression. A retrospective review of a single institutional experience with PCATCL identified 3 patients (mean age 54; range 49–62) with papules or nodules on the ear. Lesional biopsies demonstrated a dense diffuse dermal infiltrate of atypical lymphocytes with a Grenz zone in 2 cases and focal epidermotropism in 1 case. The atypical lymphocytes were predominantly CD3 and CD8 positive with expression of cytotoxic marker TIA1. Staging evaluation failed to reveal systemic disease. Two patients underwent local excision, and the third received local radiation therapy all with complete response and no disease recurrence at last follow-up 3 months (range 2–5 months). Our cases add to the existing limited literature on the clinical and histopathological features of PCATCL. We also performed an updated systematic literature view of the entity.